Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ADVANCED ONCOTHERAPY PLC. We currently have 5 research reports from 3 professional analysts.
Frequency of research reports
Research reports on
ADVANCED ONCOTHERAPY PLC
ADVANCED ONCOTHERAPY PLC
Delivery of LIGHT
15 Mar 17
AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction work on its Harley Street site expected to commence this month following preliminary assessment work. Meanwhile, individual modules for the LIGHT system are being integrated and tested in Geneva. At the March 2017 investor presentations, AVO provided a revised timeline for completion of the London Proton Therapy Centre, first patient treatments, and an update on its commercial and financial strategies.
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
Small Cap Breakfast
24 Feb 17
GBGI—Schedule One update from integrated provider of international benefits insurance. Raising £32m at 150p. Admission expected tomorrow. Anglo African Oil & Gas— Admission expected early March. Acquiring stake in producing near offshore field in the Republic of the Congo. Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb.
20 Feb 17
Steve Mnuchin, US Treasury Secretary, rather clouded Trump's revolutionary picture when speaking at his first press conference last week. Possibly he was under orders to leave key details for Trump himself to divulge at tomorrow's State of the Union Address or, just maybe, he is still confused as the rest of us. Whatever, in failing to provide any detail regarding the much anticipated corporate and personal tax reform packages championed during the Presidential campaign and, instead adopting the prudent view that the impact from the Republican's prospective fiscal policy will not be felt until 2018, initially unnerved the US markets on Friday. Investors were certainly left considering the giant injection of new spending to rebuild the country's tired infrastructure was going to take more time to deliver than currently expected although, more positively Mr Mnuchin did appear to be watering down the President's earlier attack on 'currency manipulator' China. As a result, the Dow Jones fell over 75 points during Friday's morning trade before the wall of money being liberated from global government bond markets flooded back in to ensure all three principal indices clawed back into the positive with the Industrial Average itself scaping a fractional gain, albeit sufficient for it to chalk up its 11th consecutive record closing. Asia by comparison was weaker across the board this morning, with Japan leading the decline as Nikkei sentiment again pivoted downward on modest Yen:US$ gains, dragging the Chinese indices with it while the commodity-rich ASX continued to nurse losses amongst its minerals plays. This week's primary macro focus will, of course, be on tomorrow's President's speech and to a lesser extent further comments anticipated from various Fed officials regarding prospective interest rate policy. No significant macro data is expected from the UK today, although the EU is due to publish a batch of statistics, ranging from M3 Money Supply, Services/Consumer sentiment and Industrial Confidence while the US, similarly, is expected to deliver January Durable Goods Orders and Pending Home Sales before FOMC member Robert Kaplan is scheduled to speak. UK corporates due to publish earnings or trading updates include Bunzl (BNZL.L), McColl's Retail Group (MCLS.L), Persimmon (PSN.L), Senior (SNR.L), Trinity Mirror (TNI.L) and Volex (VLX.L). London is seen drawing on the late enthusiasm than powered the US indices into the positive on Friday, with the FTSE-100 seen rising some 20 points in early trading. Investors will, however, be keen to learn more from the London Stock Exchange (LSE.L), given comments that emerged in the media late Sunday, suggesting that regulatory impositions, such as the sale of its Italian fixed income trading platform, were so overwhelming that the planned €29bn merger with Germany's Deutsche Börse was now at risk.
The Quest for Dividends
01 Feb 17
The Dow Jones Index has just breached the 20,000 mark, the first time in its 131- year history that it has done so, whilst the FTSE-100 Index has also been at record levels in recent weeks. The election of the controversial Donald Trump as the new US President, and more specifically the impact of his planned expansionist economic policies, have boosted stock markets, both in the US and in the UK.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017